EyePoint Inc
eyepoint.bioWhat Do They Do?
Develops sustained-delivery medicines for patients with serious retinal diseases and licenses ophthalmic drug rights to pharmaceutical partners.
10-K for FY2025, filed Mar 5, 2026
How Do They Make Money?
Most revenue comes from license and collaboration arrangements: partners pay upfront for rights or when milestones are achieved. Royalties arrive when partners sell licensed products, while product revenue comes from supplying products to commercial partners.
10-K for FY2025, filed Mar 5, 2026License and collaboration agreement revenue — The Company analyzes each element of its license and collaboration arrangements to determine…View ↗
The Company recognizes sales-based milestone payments as revenue upon the achievement of the cumulative sales amount specified in the…View ↗
Royalties — The Company recognizes revenue from license arrangements with its commercial partners’ net sales of products. Such revenues are…View ↗
For the years ended December 31, 2025 and 2024, the Company’s product revenues were primarily from the Company’s existing supply agreements…View ↗
-
10-K for FY2025, filed Mar 5, 2026
FY2025 revenue by product or service ↗
$31.4M
-
10-K for FY2025, filed Mar 5, 2026
$31.4M ↗
| Segment | Share | Revenue | How money arrives |
|---|---|---|---|
|
Product sales, net
Sold outright
|
5.1%
FY2022: 96%
|
Product sales, net, FY2025
$1.6M Sources
|
Sold outright |
|
License and Collaboration Agreement
Licensed
10-K for FY2025, filed Mar 5, 2026 |
53%
FY2022: 0.9%
|
License and Collaboration Agreement, FY2025
$16.7M Sources
|
Licensed |
|
Royalty Income
Licensed
10-K for FY2025, filed Mar 5, 2026 |
42%
FY2022: 2.8%
|
Royalty Income, FY2025
$13M Sources
|
Licensed |
Who Are Their Customers?
EyePoint licenses product rights directly to partners such as ANI and Ocumension. It also supplies products to commercial partners, which commercialize them in their territories.
10-K for FY2025, filed Mar 5, 2026On May 17, 2023, the Company entered into a PRA with ANI. Under the PRA, the Company granted to ANI an exclusive and sublicensable right…View ↗
The Company and ANI also entered into a commercial supply agreement (CSA), pursuant to which, during the term of the PRA, the Company…View ↗
The Company entered into an Exclusive License Agreement on November 2, 2018, as amended by a Memorandum of Understanding dated March 1…View ↗
Do Revenues Turn Into Profits?
No. It lost $232M in FY2025.
10-K for FY2025, filed Mar 5, 2026
−$243.4MView ↗
10-K for FY2025, filed Mar 5, 2026
−$232MView ↗
10-K for FY2025, filed Mar 5, 2026
−$243.4MView ↗
How Are They Changing?
- Net income
-
Sources
10-Q for Q2 FY2026, filed Aug 5, 2026
−$94.5MView ↗
- ▲ +59% (Loss)
- vs −$59.4M in Q2 FY2025
10-Q for Q2 FY2026, filed Aug 5, 2026
Open tableView ↗
-
Aug 17, 2026
LUGANO missed its primary endpoint in the full trial dataset
An ad hoc analysis excluding an asymmetric group found non-inferiority; LUCIA topline data are expected in Q4 2026.
Sources
8-K, filed Aug 17, 2026
Topline data from LUCIA, the second pivotal Phase 3 clinical trial in wet AMD, expected in Q4 2026 with potential FDA New Drug Application…View ↗
Shrinking. Revenue fell 15% in 4 years, from $36.9M in FY2021 to $31.4M in FY2025, about 4% a year.
Partner-led commercialization
The older report describes YUTIQ as marketed by EyePoint; the latest describes a license of YUTIQ rights to ANI and product supply to that partner.
10-K for FY2022, filed Mar 10, 2023 10-K for FY2025, filed Mar 5, 2026Our commercial product, YUTIQ®, is a once every three-year treatment for chronic non-infectious uveitis affecting the posterior segment of…View ↗
Who Do They Compete With?
Competes with REGENXBIO, Adverum Biotechnologies, 4D Molecular Therapeutics, Merck, Ollin Biosciences, Ocular Therapeutix, Kodiak Sciences, and Oculis Holding
10-K for FY2025, filed Mar 5, 2026REGENXBIO Inc., Adverum Biotechnologies, Inc., 4D Molecular Therapeutics (4DMT), Merck (EyeBio), Ollin Biosciences, Inc., as well as…View ↗
Loading...
